Testing how long to take PD-1 therapy for melanoma
Part of Cancer, Skin clinical trials.
This trial studies whether people with metastatic melanoma should take PD-1 immunotherapy continuously or only for a limited time. It aims to find a schedule that keeps the cancer under control while possibly reducing treatment burden.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 or older and eligible for publicly funded PD-1 treatment in your province
- Have melanoma that has spread or cannot be removed by surgery (stage III/IV)
- Be starting this study soon after beginning PD-1 treatment (or soon before), and have a recent scan to confirm no new progression
- Be able and willing to fill out quality-of-life and health questionnaire forms in English or French
- Be willing to follow the study’s treatment schedule—especially stopping PD-1 if you’re assigned to intermittent dosing
- If you have brain metastases, they must be stable (no recent growth or new lesions) before joining
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system responds to PD-1/PD-L1 immunotherapy (drugs like Keytruda or Opdivo) for advanced melanoma, lung cancer, and similar cancers. It involves regular blood tests to track your immune cells, which may help doctors understand why these treatments work for some people better than others.
This study checks an “interim” whole-body scan (PET-CT) partway through treatment to see how well anti-PD-1 immunotherapy (nivolumab or pembrolizumab) is working for advanced melanoma. It may help doctors better understand early treatment response and guide next steps.
This trial tests if an immunotherapy drug (anti-PD1) can change atypical (dysplastic) moles in people who have had melanoma. It may help understand how these drugs affect mole cells.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a new drug called OPM-101 combined with an immunotherapy (anti-PD-1) for people with advanced melanoma that has stopped responding to anti-PD-1 treatment. The goal is to see if the combination can overcome resistance and shrink tumors.
This trial tests early anti-PD-1 therapy for people with stage IIB or IIC melanoma, or stage III (N1c). It aims to see if starting treatment sooner helps prevent the cancer from coming back.
Hear when a new Unresectable/Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.